MGX
HealthcareMetagenomi, Inc.
$1.71
+$0.04 (+2.40%)
Jan 5, 2026
Price History (1Y)
Analysis
Metagenomi, Inc. is a biotechnology company operating in the healthcare sector. With a market capitalization of $64.20 million, revenue of $30.91 million (TTM), and 124 employees, it is a relatively small player in its industry. The company's financial health is concerning, with negative profitability metrics across the board. Gross Margin stands at -210.9%, Operating Margin at -263.8%, and Profit Margin at -287.1%. Returns on Equity and Assets are also negative, at -40.9% and -19.0%, respectively. The balance sheet shows a debt-to-equity ratio of 23.35, but a current ratio of 6.42 indicates sufficient liquidity. Cash reserves total $184.11 million, while debt amounts to $41.66 million. Valuation metrics are also noteworthy. The company's P/E Ratio (TTM) is not applicable, and the Forward P/E is -0.94. Revenue Growth (YoY) is at -24.8%. The Price to Book ratio stands at 0.36, while Price to Sales is 2.08. EV/EBITDA is 0.92.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Metagenomi, Inc.
Metagenomi, Inc., a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. Its genome editing toolbox includes nuclease-based genome editing, base editors, RNA-mediated integration, including prime editing, and DNA-mediated integration, such CRISPR-associated transposases. The company has a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop and commercialize investigational medicines using genome editing technologies; and a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited TCR-based therapeutic products exclusively in the field of treatment, prevention, or diagnosis of any human cancer. Metagenomi, Inc. was incorporated in 2016 and is headquartered in Emeryville, California.
Visit website →Key Statistics
- Market Cap
- $64.20M
- P/E Ratio
- N/A
- 52-Week High
- $4.00
- 52-Week Low
- $1.23
- Avg Volume
- 581.89K
Company Info
- Industry
- Biotechnology
- Exchange
- NMS
- Country
- United States
- Employees
- 124